Proteomic analysis of acute kidney injury: Biomarkers to mechanisms

Proteomics - Clinical Applications

Volumn 5, Issue 1-2, 2011, Pages 67-77

  Bennett, Michael R ^a   Devarajan, Prasad ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Acute kidney injury; Biomarkers

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CYCLOSPORIN A; HEPCIDIN; HERMES ANTIGEN; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OROSOMUCOID; PIGMENT EPITHELIUM DERIVED FACTOR;

ACUTE KIDNEY FAILURE; CLINICAL EVALUATION; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY BYPASS SURGERY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; NEPHROTOXICITY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TARGETING; PROTEIN URINE LEVEL; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ACUTE KIDNEY INJURY; BIOLOGICAL MARKERS; HUMANS; METABOLOMICS; PROTEOMICS;

EID: 79251543955     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000066     Document Type: Review

References (87)

1. Hoste, E. A., Schurgers, M., Epidemiology of acute kidney injury: how big is the problem? Crit. Care Med. 2008, 36, S146-S151.
2. Chertow, G. M., Burdick, E., Honour, M., Bonventre, J. V. et al., Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J. Am. Soc. Nephrol. 2005, 16, 3365-3370.
3. Devarajan, P., Proteomics for biomarker discovery in acute kidney injury. Semin. Nephrol. 2007, 27, 637-651.
4. Kellum, J. A., Levin, N., Bouman, C., Lameire, N., Developing a consensus classification system for acute renal failure. Curr. Opin. Crit. Care 2002, 8, 509-514.
5. American Society of Nephrology Renal Research Report. J. Am. Soc. Nephrol. 2005, 16, 1886-1903.
6. Bellomo, R., Ronco, C., Kellum, J. A., Mehta, R. L. et al., Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 2004, 8, R204-R212.
7. Ricci, Z., Cruz, D., Ronco, C., The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int. 2008, 73, 538-546.
8. Mehta, R. L., Kellum, J. A., Shah, S. V., Molitoris, B. A. et al., Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 2007, 11, R31.
9. Soni, S. S., Ronco, C., Katz, N., Cruz, D. N., Early diagnosis of acute kidney injury: the promise of novel biomarkers. Blood Purif. 2009, 28, 165-174.
10. Chertow, G. M., Lee, J., Kuperman, G. J., Burdick, E. et al., Guided medication dosing for inpatients with renal insufficiency. J Am Med Assoc 2001, 286, 2839-2844.
11. Liangos, O., Wald, R., O'Bell, J. W., Price, L. et al., Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin. J. Am. Soc. Nephrol. 2006, 1, 43-51.
12. de Mendonca, A., Vincent, J. L., Suter, P. M., Moreno, R. et al., Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med. 2000, 26, 915-921.
13. Bagshaw, S. M., George, C., Dinu, I., Bellomo, R., A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol. Dial. Transplant. 2008, 23, 1203-1210.
14. Ostermann, M., Chang, R. W., Acute kidney injury in the intensive care unit according to RIFLE. Crit. Care Med. 2007, 35, 1837-1843; quiz 1852.
15. Devarajan, P., Update on mechanisms of ischemic acute kidney injury. J. Am. Soc. Nephrol. 2006, 17, 1503-1520.
16. Vaidya, V. S., Ferguson, M. A., Bonventre, J. V., Biomarkers of acute kidney injury. Annu. Rev. Pharmacol. Toxicol. 2008, 48, 463-493.
17. Allgren, R. L., Marbury, T. C., Rahman, S. N., Weisberg, L. S. et al., Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N. Engl. J. Med. 1997, 336, 828-834.
18. Hirschberg, R., Kopple, J., Lipsett, P., Benjamin, E. et al., Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int. 1999, 55, 2423-2432.
19. Herget-Rosenthal, S., Marggraf, G., Husing, J., Goring, F. et al., Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004, 66, 1115-1122.
20. Hewitt, S. M., Dear, J., Star, R. A., Discovery of protein biomarkers for renal diseases. J. Am. Soc. Nephrol. 2004, 15, 1677-1689.
21. Letellier, G., Desjarlais, F., Analytical interference of drugs in clinical chemistry: II - the interference of three cephalosporins with the determination of serum creatinine concentration by the Jaffe reaction. Clin. Biochem. 1985, 18, 352-356.
22. Weber, J. A., van Zanten, A. P., Interferences in current methods for measurements of creatinine. Clin. Chem. 1991, 37, 695-700.
23. Carrie, B. J., Golbetz, H. V., Michaels, A. S., Myers, B. D., Creatinine: an inadequate filtration marker in glomerular diseases. Am. J. Med. 1980, 69, 177-182.
24. Zerhouni, E., Medicine. The NIH Roadmap. Sci. 2003, 302, 63-72.
25. Han, W. K., Bonventre, J. V., Biologic markers for the early detection of acute kidney injury. Curr. Opin. Crit. Care 2004, 10, 476-482.
26. Zhou, H., Hewitt, S. M., Yuen, P. S., Star, R. A., Acute kidney injury biomarkers - needs, present status, and future promise. Nephrol. Self Assess. Program 2006, 5, 63-71.
27. Thongboonkerd, V., Proteomic analysis of renal diseases: unraveling the pathophysiology and biomarker discovery. Expert Rev. Proteomics 2005, 2, 349-366.
28. Devarajan, P., Proteomics for the investigation of acute kidney injury. Contrib. Nephrol. 2008, 160, 1-16.
29. Devarajan, P., Emerging biomarkers of acute kidney injury. Contrib. Nephrol. 2007, 156, 203-212.
30. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69, 89-95.
31. Mishra, J., Ma, Q., Prada, A., Mitsnefes, M. et al., Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 2003, 14, 2534-2543.
32. Nguyen, M. T., Devarajan, P., Biomarkers for the early detection of acute kidney injury. Pediatr. Nephrol. 2008, 23, 2151-2157.
33. Nickolas, T. L., Barasch, J., Devarajan, P., Biomarkers in acute and chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2008, 17, 127-132.
34. Parikh, C. R., Jani, A., Mishra, J., Ma, Q. et al., Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am. J. Transplant. 2006, 6, 1639-1645.
35. Sigdel, T. K., Kaushal, A., Gritsenko, M., Norbeck, A. D. et al., Shotgun proteomics identifies proteins specific for acute renal transplant rejection. Proteomics Clin. Appl. 2010, 4, 32-47.
36. Wu, J., Chen, Y. D., Gu, W., Urinary proteomics as a novel tool for biomarker discovery in kidney diseases. J. Zhejiang Univ. Sci. B 1958, 11, 227-237.
37. Vestergaard, P., Leverett, R., Constancy of urinary creatinine excretion. J. Lab. Clin. Med. 1958, 51, 211-218.
38. Scott, P. J., Hurley, P. J., Demonstration of individual variation in constancy of 24-hour urinary creatinine excretion. Clin. Chim. Acta 1968, 21, 411-414.
39. Miller, W. G., Bruns, D. E., Hortin, G. L., Sandberg, S. et al., Current issues in measurement and reporting of urinary albumin excretion. Clin. Chem. 2009, 55, 24-38.
40. Waikar, S. S., Sabbisetti, V. S., Bonventre, J. V., Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int. 2010, 78, 486-494.
41. Nguyen, M. T., Ross, G. F., Dent, C. L., Devarajan, P., Early prediction of acute renal injury using urinary proteomics. Am. J. Nephrol. 2005, 25, 318-326.
42. Nguyen, M. T., Dent, C. L., Ross, G. F., Harris, N. et al., Urinary aprotinin as a predictor of acute kidney injury after cardiac surgery in children receiving aprotinin therapy. Pediatr. Nephrol. 2008, 23, 1317-1326.
43. Devarajan, P., Krawczeski, C., Nguyen, M. T., Kathman, T. S. et al., Proteomic identification of early biomarkers of acute kidney injury after cardiac surgery in children. Am. J. Kidney Dis. 2010, 56, 632-642.
44. Nickolas, T. L., O'Rourke, M. J., Yang, J., Sise, M. E. et al., Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann. Intern Med. 2008, 148, 810-819.
45. Mangano, D. T., Miao, Y., Vuylsteke, A., Tudor, I. C. et al., Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. J. Am. Med. Assoc. 2007, 297, 471-479.
46. Pasquali, S. K., Hall, M., Li, J. S., Peterson, E. D. et al., Safety of aprotinin in congenital heart operations: results from a large multicenter database. Ann. Thorac. Surg. 2010, 90, 14-21.
47. Bosman, M., Royston, D., Aprotinin and renal dysfunction. Expert Opin. Drug Saf. 2008, 7, 663-677.
48. Ho, J., Lucy, M., Krokhin, O., Hayglass, K. et al., Mass spectrometry-based proteomic analysis of urine in acute kidney injury following cardiopulmonary bypass: a nested case-control study. Am. J. Kidney Dis. 2009, 53, 584-595.
49. Wenderfer, S. E., Dubinsky, W. P., Hernandez-Sanabria, M., Braun, M. C., Urine proteome analysis in murine nephrotoxic serum nephritis. Am. J. Nephrol. 2009, 30, 450-458.
50. Bennett, M. R., Ravipati, N., Ross, G., Nguyen, M. T. et al., Using proteomics to identify preprocedural risk factors for contrast induced nephropathy. Proteomics Clin. Appl. 2008, 2, 1058-1064.
51. O'Riordan, E., Orlova, T. N., Podust, V. N., Chander, P. N. et al., Characterization of urinary peptide biomarkers of acute rejection in renal allografts. Am. J. Transplant. 2007, 7, 930-940.
52. Valore, E. V., Park, C. H., Quayle, A. J., Wiles, K. R. et al., Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J. Clin. Invest. 1998, 101, 1633-1642.
53. Aregger, F., Pilop, C., Uehlinger, D. E., Brunisholz, R. et al., Urinary proteomics before and after extracorporeal circulation in patients with and without acute kidney injury. J. Thorac. Cardiovasc. Surg. 2010, 139, 692-700.
54. Zhou, H., Pisitkun, T., Aponte, A., Yuen, P. S. et al., Exosomal Fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int. 2006, 70, 1847-1857.
55. Pisitkun, T., Shen, R. F., Knepper, M. A., Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci. USA 2004, 101, 13368-13373.
56. Zhou, H., Yuen, P. S., Pisitkun, T., Gonzales, P. A. et al., Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. Kidney Int. 2006, 69, 1471-1476.
57. Puigmule, M., Lopez-Hellin, J., Sune, G., Tornavaca, O. et al., Differential proteomic analysis of cyclosporine A-induced toxicity in renal proximal tubule cells. Nephrol. Dial. Transplant. 2009, 24, 2672-2686.
58. Schlieper, G., Westenfeld, R., Brandenburg, V., Ketteler, M., Inhibitors of calcification in blood and urine. Semin. Dial. 2007, 20, 113-121.
59. Hart, T. C., Gorry, M. C., Hart, P. S., Woodard, A. S. et al., Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J. Med. Genet. 2002, 39, 882-892.
60. Sejdiu, I., Torffvit, O., Decreased urinary concentration of Tamm-Horsfall protein is associated with development of renal failure and cardiovascular death within 20 years in type 1 but not in type 2 diabetic patients. Scand. J. Urol. Nephrol. 2008, 42, 168-174.
61. Dawson, D. W., Volpert, O. V., Gillis, P., Crawford, S. E. et al., Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999, 285, 245-248.
62. Matsuyama, K., Ogata, N., Matsuoka, M., Shima, C. et al., Relationship between pigment epithelium-derived factor (PEDF) and renal function in patients with diabetic retinopathy. Mol. Vis. 2008, 14, 992-996.
63. Nicholson, J. K., Lindon, J. C., Holmes, E., 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29, 1181-1189.
64. Cottret, L., Wildridge, D., Vinson, F., Barrett, M. P. et al., MetExplore: a web server to link metabolomic experiments and genome-scale metabolic networks. Nucleic Acids Res. 2010, 38, W132-W137.
65. Fiehn, O., Metabolomics - the link between genotypes and phenotypes. Plant Mol. Biol. 2002, 48, 155-171.
66. Beger, R. D., Holland, R. D., Sun, J., Schnackenberg, L. K. et al., Metabonomics of acute kidney injury in children after cardiac surgery. Pediatr Nephrol. 2008, 23, 977-984.
67. Goldstein, D. S., Mezey, E., Yamamoto, T., Aneman, A. et al., Is there a third peripheral catecholaminergic system? Endogenous dopamine as an autocrine/paracrine substance derived from plasma DOPA and inactivated by conjugation. Hypertens. Res. 1995, 18, S93-S99.
68. Lee, M. R., Dopamine and the kidney: ten years on. Clin. Sci. (Lond.) 1993, 84, 357-375.
69. Pestana, M., Jardim, H., Serrao, P., Soares-da-Silva, P. et al., Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease. Kidney Blood Press. Res. 1998, 21, 59-65.
70. Wolfovitz, E., Grossman, E., Folio, C. J., Keiser, H. R. et al., Derivation of urinary dopamine from plasma dihydroxyphenylalanine in humans. Clin. Sci. (Lond.) 1993, 84, 549-557.
71. Mishra, J., Mori, K., Ma, Q., Kelly, C. et al., Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am. J. Nephrol. 2004, 24, 307-315.
72. Mishra, J., Mori, K., Ma, Q., Kelly, C. et al., Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol. 2004, 15, 3073-3082.
73. Haase, M., Bellomo, R., Devarajan, P., Schlattmann, P. et al., Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am. J. Kidney Dis. 2009, 54, 1012-1024.
74. Mishra, J., Dent, C., Tarabishi, R., Mitsnefes, M. M. et al., Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365, 1231-1238.
75. Hirsch, R., Dent, C., Pfriem, H., Allen, J. et al., NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr. Nephrol. 2007, 22, 2089-2095.
76. Mishra, J., Ma, Q., Kelly, C., Mitsnefes, M. et al., Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr. Nephrol. 2006, 21, 856-863.
77. Wheeler, D. S., Devarajan, P., Ma, Q., Harmon, K. et al., Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit. Care Med. 2008, 36, 1297-1303.
78. Devarajan, P., Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark. Med. 2010, 4, 265-280.
79. Bennett, M., Dent, C. L., Ma, Q., Dastrala, S. et al., Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin. J. Am. Soc. Nephrol. 2008, 3, 665-673.
80. Dent, C. L., Ma, Q., Dastrala, S., Bennett, M. et al., Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Crit. Care 2007, 11, R127.
81. Ichimura, T., Bonventre, J. V., Bailly, V. r., Wei, H. et al., Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after Injury. J. Biol. Chem. 1998, 273, 4135-4142.
82. Vaidya, V. S., Ramirez, V., Ichimura, T., Bobadilla, N. A., Bonventre, J. V., Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am. J. Physiol. Renal. Physiol. 2006, 290, F517-F529.
83. Vaidya, V. S., Waikar, S. S., Ferguson, M. A., Collings, F. B. et al., Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin. Transl. Sci. 2008, 1, 200-208.
84. Vaidya, V. S., Ford, G. M., Waikar, S. S., Wang, Y. et al., A rapid urine test for early detection of kidney injury. Kidney Int. 2009, 76, 108-114.
85. Pepe, M. S., Feng, Z., Janes, H., Bossuyt, P. M. et al., Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J. Natl. Cancer Inst. 2008, 100, 1432-1438.
86. Braunwald, E., Biomarkers in heart failure. N. Engl. J. Med. 2008, 358, 2148-2159.
87. Peacock, W. F., De Marco, T., Fonarow, G. C., Diercks, D. et al., Cardiac troponin and outcome in acute heart failure. N. Engl. J. Med. 2008, 358, 2117-2126.